

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



太 睿 國 際 控 股 有 限 公 司

PacRay International Holdings Limited

(Incorporated in Bermuda with limited liability)

(Stock code: 1010)

PROFIT WARNING

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of PacRay International Holdings Limited (the “**Company**”) and its subsidiaries (collectively referred to as the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the information currently available to the management of the Company (the “**Management**”), including the unaudited consolidated management accounts of the Group for the six months ended 30 June 2021, it is expected that the Group will record:

- (i) an increase in revenue by approximately 54.16% to approximately HK\$54.47 million for the six months ended 30 June 2021, as compared with approximately HK\$35.33 million for the six months ended 30 June 2020;
- (ii) an increase in gross profit by approximately 14.73% to approximately HK\$13.40 million for the six months ended 30 June 2021, as compared with approximately HK\$11.68 million for the six months ended 30 June 2020; and
- (iii) a loss attributable to owners of the parent of HK\$10.86 million for the six months ended 30 June 2021, as compared with approximately HK\$1.19 million for the six months ended 30 June 2020.

The increase in the revenue for the six months ended 30 June 2021 was mainly due to (i) a stable volume of the sale orders for integrated circuit and semi-conductor products; and (ii) an increasing volume of the custodian services for the aircraft business. On the other hand, the intensive competitiveness and unfavorable business environment has exerted a noticeable pressure on the price charged by the Group on its clients, as well as the material costs and labor costs, which altogether led to a narrower gross profit margin. Finally, the Group recorded a shared loss from its investments in associate of approximately HK\$6.28 million for the six months ended 30 June 2021, as compared with nil for the six months ended 30 June 2020. Notwithstanding the abovementioned, the Management would like to emphasize that the increasement of the loss attributable to owners of the parent mainly comprised non-cash items (e.g., the shared loss from the investment in associate) and has no effect on the Group’s daily operations and cash flow.

The Management is still in the process of finalizing the interim results of the Group for the six months ended 30 June 2021. The information contained in this announcement is only based on a preliminary review of the unaudited consolidated management accounts of the Group and other information currently available to the Board, which is subject to possible adjustments arising from further review. The interim results of the Group for the six months ended 30 June 2021, which is expected to be published on 27 August 2021, may be different to the information referred in this announcement.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
PacRay International Holdings Limited
Duan Hongtao
Chairman

Hong Kong, 26 August 2021

As at the date of this announcement, the Board of the Company comprises nine Directors. The executive Directors are Mr. Duan Hongtao (chairman), Ms. Li Weina, Ms. Liu Wenjia, Mr. Xu Yinsheng and Mr. Zhang Fumin; the non-executive Director is Mr. Zhou Danqing; and the independent non-executive Directors are Ms. Ching Ching, Dr. Song Donglin and Dr. Zhang Shengdong.